The vaccine is 66% effective overall in preventing moderate to severe COVID-19 28 days after vaccination.
Johnson & Johnson (J&J) announced on Jan. 29, 2021 that data from a Phase III trial for its COVID-19 vaccine candidate showed that the vaccine is 66% effective overall in preventing moderate to severe COVID-19 28 days after vaccination.
The randomized double-blind, placebo-controlled clinical trial was designed to determine the safety and efficacy of a single-dose vaccine versus placebo in adults 18 years old and older, J&J said in a company press release. Participants were enrolled in the United States, Central and South America, and South Africa and the vaccine showed an effectiveness of 72% in the United States, 66% in Latin America, and 57% in South Africa, 28 days post-vaccination.
The vaccine also showed to be 85% effective in preventing severe disease across all regions studied, with efficacy against severe disease increasing over time. No cases of COVID-19 were reported in vaccinated participants after day 49, according to the press release.
“These topline results with a single-shot COVID-19 vaccine candidate represent a promising moment. The potential to significantly reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with just one immunization, is a critical component of the global public health response,” said Paul Stoffels, MD, vice-chairman of the executive committee and J&J’s chief scientific officer, in the press release. “A one-shot vaccine is considered by the World Health Organization to be the best option in pandemic settings, enhancing access, distribution, and compliance. Eighty-five percent efficacy in preventing severe COVID-19 disease and prevention of COVID-19-related medical interventions will potentially protect hundreds of millions of people from serious and fatal outcomes of COVID-19. It also offers the hope of helping ease the huge burden placed on healthcare systems and communities.”
“Johnson & Johnson embarked on the global effort to combat the COVID-19 pandemic a year ago, and has brought the full force of our capabilities, as well as tremendous public-private partnerships, to enable the development of a single-shot vaccine. Our goal all along has been to create a simple, effective solution for the largest number of people possible, and to have maximum impact to help end the pandemic,” said Alex Gorsky, chairman, board of directors, and J&J’s CEO,in the press release. “We’re proud to have reached this critical milestone and our commitment to address this global health crisis continues with urgency for everyone, everywhere.”
Source: Johnson & Johnson
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.